NephroDI Therapeutics, a Biolocity portfolio company, has made waves in the medical field with its recent agreement to develop a first-in-class treatment for a rare genetic disease affecting the kidneys. This development brings new hope to patients and their families who have been waiting for a targeted therapy to address congenital Nephrogenic Diabetes Insipidus (NDI). This collaboration is a testament to the power of scientific innovation and industry partnerships in driving advancements in healthcare and improving patient outcomes.
Learn more about this exciting news here.
You must be logged in to post a comment.